{"id":35797,"date":"2025-06-23T16:15:04","date_gmt":"2025-06-23T08:15:04","guid":{"rendered":"https:\/\/flcube.com\/?p=35797"},"modified":"2025-06-23T16:15:05","modified_gmt":"2025-06-23T08:15:05","slug":"jiangxi-rimag-to-acquire-70-stake-in-guangzhou-gaomai-for-rmb-54-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35797","title":{"rendered":"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million"},"content":{"rendered":"\n<p>China-based Jiangxi Rimag Group Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2522:HKG\">HKG: 2522<\/a>) is set to acquire a 70% stake in compatriot firm Guangzhou Gaomai Health Technology Co., Ltd for RMB 54 million (USD 7.5 million). Upon deal closure, Gaomai Health will become a subsidiary of Rimag.<\/p>\n\n\n\n<p><strong>Acquisition Details<\/strong><br>The acquisition of Gaomai Health, which specializes in nuclear medicine imaging technology and operational management services, is expected to significantly enhance Rimag&#8217;s development, management, and operational capabilities in nuclear medicine projects. This strategic move aims to promote the application of radiopharmaceuticals in PET\/CT business and expand the imaging center market and related services in overseas and regional markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025062200010_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025062200010_c.\"><\/object><a id=\"wp-block-file--media-e01e5b3c-2ae8-4328-a189-2d9fa1cc171b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025062200010_c.pdf\">2025062200010_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025062200010_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e01e5b3c-2ae8-4328-a189-2d9fa1cc171b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4170,1914,1940],"class_list":["post-35797","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gaomai-health-technology","tag-hkg-2522","tag-rimag-group"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake in compatriot firm Guangzhou Gaomai Health Technology Co., Ltd for RMB 54 million (USD 7.5 million). Upon deal closure, Gaomai Health will become a subsidiary of Rimag.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35797\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million\" \/>\n<meta property=\"og:description\" content=\"China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake in compatriot firm Guangzhou Gaomai Health Technology Co., Ltd for RMB 54 million (USD 7.5 million). Upon deal closure, Gaomai Health will become a subsidiary of Rimag.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35797\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T08:15:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-23T08:15:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35797#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35797\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million\",\"datePublished\":\"2025-06-23T08:15:04+00:00\",\"dateModified\":\"2025-06-23T08:15:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35797\"},\"wordCount\":117,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gaomai Health Technology\",\"HKG: 2522\",\"Rimag Group\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35797#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35797\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35797\",\"name\":\"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2025-06-23T08:15:04+00:00\",\"dateModified\":\"2025-06-23T08:15:05+00:00\",\"description\":\"China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake in compatriot firm Guangzhou Gaomai Health Technology Co., Ltd for RMB 54 million (USD 7.5 million). Upon deal closure, Gaomai Health will become a subsidiary of Rimag.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35797#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35797\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35797#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake in compatriot firm Guangzhou Gaomai Health Technology Co., Ltd for RMB 54 million (USD 7.5 million). Upon deal closure, Gaomai Health will become a subsidiary of Rimag.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35797","og_locale":"en_US","og_type":"article","og_title":"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million","og_description":"China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake in compatriot firm Guangzhou Gaomai Health Technology Co., Ltd for RMB 54 million (USD 7.5 million). Upon deal closure, Gaomai Health will become a subsidiary of Rimag.","og_url":"https:\/\/flcube.com\/?p=35797","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-23T08:15:04+00:00","article_modified_time":"2025-06-23T08:15:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35797#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35797"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million","datePublished":"2025-06-23T08:15:04+00:00","dateModified":"2025-06-23T08:15:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35797"},"wordCount":117,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gaomai Health Technology","HKG: 2522","Rimag Group"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35797#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35797","url":"https:\/\/flcube.com\/?p=35797","name":"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2025-06-23T08:15:04+00:00","dateModified":"2025-06-23T08:15:05+00:00","description":"China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake in compatriot firm Guangzhou Gaomai Health Technology Co., Ltd for RMB 54 million (USD 7.5 million). Upon deal closure, Gaomai Health will become a subsidiary of Rimag.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35797#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35797"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35797#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35797"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35797\/revisions"}],"predecessor-version":[{"id":35799,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35797\/revisions\/35799"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}